乌克兰敖德萨州高耐药结核发病率地区常规实施Xpert MTB/RIF检测的诊断性能与影响
该研究在乌克兰结核病发病率最高的敖德萨州评估常规使用Xpert MTB/RIF检测的性能及其对治疗结局的影响。结果显示,涂片阳性痰标本检测结核的敏感性为93.7%,涂片阴性为69.5%,利福平耐药敏感性为93.4%;1周内启动治疗提高成功结局比例,但Xpert引入未显著改善治疗结局。
要点
- 涂片阳性痰标本Xpert检测结核敏感性93.7%,涂片阴性为69.5%。
- 利福平耐药检测敏感性为93.4%。
- 1周内启动治疗与更高成功结局比例相关(60.1% vs 25.9%)。
核心结论
- Xpert MTB/RIF在乌克兰高结核及耐药结核发病率地区常规实施的性能与类似地区一致。
- 快速分子检测推广需结合其他规划改进才可能改善治疗结果。
研究设计与样本
- 在敖德萨州常规使用Xpert MTB/RIF的背景下评估其性能及对治疗结局的影响。
主要发现
- Xpert检测结核的敏感性在涂片阳性痰标本为93.7%(1165/1243),涂片阴性为69.5%(448/645)。
- Xpert检测利福平耐药的敏感性为93.4%(1212/1298)。
- 使用Xpert检测结核的中位时间为0天。
- 1周内启动治疗的成功结局比例为60.1%,而较晚启动为25.9%(RR=1.86,95%CI=1.46-2.42)。
- Xpert MTB/RIF引入后治疗结局无显著改善(57.2% vs 46.2%;RR=0.93,95%CI=0.77-1.12)。
临床怎么用
- 在资源有限的高耐药结核地区,Xpert MTB/RIF可用于快速检测结核及利福平耐药。
- 应同时推动其他规划性改进以最大化快速检测对治疗结局的益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES AND METHODS: The Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) has been in routine use in Odessa Oblast, a region with the highest tuberculosis (TB) incidence in Ukraine, since 2013. We assessed the performance of the assay in routine settings and evaluated its effect on treatment outcomes. RESULTS: The sensitivity of Xpert for TB detection was 93.7% (1165/1243) and 69.5% (448/645) for smear-positive and smear-negative sputum specimens, respectively, and its sensitivity for rifampicin resistance was 93.4% (1212/1298). Median time to TB detection using the Xpert assay was 0 days. Treatment initiation within 1 week increased the proportion of successful outcomes (60.1% versus 25.9%, RR = 1.86, 95%CI = 1.46-2.42), but the introduction of Xpert MTB/RIF has not led to a significant improvement in treatment outcomes (57.2% versus 46.2%; RR = 0.93, 95%CI = 0.77-1.12). CONCLUSION: Performance characteristics of the Xpert assay demonstrated during its routine implementation in an area of high TB and drug-resistant TB incidence in Ukraine were in line with those demonstrated in similar settings elsewhere. Rollout of rapid molecular testing may lead to better treatment results provided that it is implemented in conjunction with other programmatic improvements.
引用
- Nikolayevskyy V, Kontsevaya I, Nikolaevskaya E, et al. Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine. Clin Microbiol Infect. 2018. PMID: 30590114. doi:10.1016/j.cmi.2018.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。